From: Clinical impact of PTEN methylation status as a prognostic marker for breast cancer
Markers | Breast cancer | Benign breast lesion | Control individuals |
---|---|---|---|
CEA (ng/ml) | |||
 Mean ± SEM | 15.8 ± 0.5 | 12.6 ± 0.6 | 11.3 ± 0.7 |
 Positivity rate | 49.1% | 12.2% | 0% |
Statistics | F = 11.5, P = 0.001, X2 = 15.6, P < 0.001 | ||
CA15.3 (ng/ml) | |||
 Mean ± SEM | 22.2 ± 0.8 | 17 ± 1 | 10.6 ± 0.3 |
 Positivity rate | 50% | 14.6% | 0% |
Statistics | F = 13.5, P < 0.001, X2 = 17.1, P < 0.001 | ||
PTEN methylation status % | |||
 Mean ± SEM | 87 ± 0.6 | 25 ± 0.7 | 12.6 ± 0.3 |
 Positivity rate | 96.4% | 0% | 0% |
Statistics | F = 350, P < 0.001, X2 = 15.6, P < 0.001 |